LEGN vs. VKTX, ASND, CERE, ROIV, JAZZ, ITCI, CYTK, ELAN, BPMC, and CTLT
Should you be buying Legend Biotech stock or one of its competitors? The main competitors of Legend Biotech include Viking Therapeutics (VKTX), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Roivant Sciences (ROIV), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Legend Biotech (NASDAQ:LEGN) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, community ranking, risk, profitability, media sentiment and institutional ownership.
Viking Therapeutics has lower revenue, but higher earnings than Legend Biotech. Viking Therapeutics is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -135.92%. Viking Therapeutics' return on equity of -18.41% beat Legend Biotech's return on equity.
Legend Biotech has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Legend Biotech presently has a consensus price target of $82.74, suggesting a potential upside of 83.49%. Viking Therapeutics has a consensus price target of $112.38, suggesting a potential upside of 65.40%. Given Legend Biotech's higher probable upside, equities research analysts clearly believe Legend Biotech is more favorable than Viking Therapeutics.
70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Legend Biotech had 12 more articles in the media than Viking Therapeutics. MarketBeat recorded 29 mentions for Legend Biotech and 17 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 0.79 beat Legend Biotech's score of 0.61 indicating that Viking Therapeutics is being referred to more favorably in the news media.
Viking Therapeutics received 540 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 79.97% of users gave Viking Therapeutics an outperform vote while only 64.13% of users gave Legend Biotech an outperform vote.
Summary
Viking Therapeutics beats Legend Biotech on 13 of the 18 factors compared between the two stocks.
Get Legend Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Legend Biotech Competitors List
Related Companies and Tools